Venture Life Group PLC Director/PDMR Shareholding (4379N)
25 September 2023 - 8:01AM
UK Regulatory
TIDMVLG
RNS Number : 4379N
Venture Life Group PLC
25 September 2023
25 September 2023
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Director Dealings
Venture Life Group plc (AIM: VLG), a leader in developing,
manufacturing and commercialising products for the self-care
market, announces that the Board has approved an 18-month extension
of the timeline in which Mr Jeremy Randall may exercise the 483,333
share options granted to him on 5 November 2013 such that these
options will now lapse on 5 May 2025 rather than 5 November
2023.
As at the time of this announcement, Mr Randall owns 1.65% of
the issued share capital of VLG and holds 2,483,333 share
options.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Securities plc (Nomad and Joint Broker) +44 (0) 20
7720 0500
Stephen Keys / Camilla Hume (Corporate Finance)
Michael Johnson (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, Italy,
The Netherlands and Sweden, the Group's product portfolio includes
some key products such as the UltraDEX and Dentyl oral care product
ranges, the Balance Active range in the area of women's intimate
healthcare, the Lift and Glucogel product ranges for hypoglycaemia,
products for fungal infections and proctology, and dermo-cosmetics
for addressing the signs of ageing. Its products are sold in over
90 countries worldwide.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its two Development & Manufacturing operations in
Italy and Sweden, the Group also provides development and
manufacturing services to companies in the medical devices and
cosmetic sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFIFSTAEISFIV
(END) Dow Jones Newswires
September 25, 2023 02:01 ET (06:01 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Venture Life (LSE:VLG)
Historical Stock Chart
Von Jan 2024 bis Jan 2025